JP2006248978A - 新規なリポソーム製剤 - Google Patents

新規なリポソーム製剤 Download PDF

Info

Publication number
JP2006248978A
JP2006248978A JP2005067469A JP2005067469A JP2006248978A JP 2006248978 A JP2006248978 A JP 2006248978A JP 2005067469 A JP2005067469 A JP 2005067469A JP 2005067469 A JP2005067469 A JP 2005067469A JP 2006248978 A JP2006248978 A JP 2006248978A
Authority
JP
Japan
Prior art keywords
liposome preparation
preparation according
liposome
dicarboxylic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005067469A
Other languages
English (en)
Japanese (ja)
Inventor
Kazushi Okada
一志 岡田
Tadayuki Ibuki
忠之 伊吹
Touken Kin
東賢 金
Tadashi Fujisawa
忠司 藤澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mebiopharm Co Ltd
Original Assignee
Mebiopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co Ltd filed Critical Mebiopharm Co Ltd
Priority to JP2005067469A priority Critical patent/JP2006248978A/ja
Priority to SI200631892T priority patent/SI1863448T1/sl
Priority to EP06737793.7A priority patent/EP1863448B1/en
Priority to ES06737793.7T priority patent/ES2529453T3/es
Priority to KR1020077023219A priority patent/KR101352490B1/ko
Priority to JP2008500977A priority patent/JP5438317B2/ja
Priority to RU2007137492/15A priority patent/RU2454229C2/ru
Priority to BRPI0608297-1A priority patent/BRPI0608297A2/pt
Priority to CN2006800159670A priority patent/CN101170995B/zh
Priority to PT67377937T priority patent/PT1863448E/pt
Priority to CA002600446A priority patent/CA2600446A1/en
Priority to AU2006223329A priority patent/AU2006223329B2/en
Priority to PL06737793T priority patent/PL1863448T3/pl
Priority to HUE06737793A priority patent/HUE024290T2/en
Priority to MX2007010996A priority patent/MX2007010996A/es
Priority to ZA200708600A priority patent/ZA200708600B/xx
Priority to NZ561569A priority patent/NZ561569A/en
Priority to PCT/US2006/008650 priority patent/WO2006099169A2/en
Priority to DK06737793.7T priority patent/DK1863448T3/en
Priority to US11/371,586 priority patent/US7829113B2/en
Publication of JP2006248978A publication Critical patent/JP2006248978A/ja
Priority to NO20075136A priority patent/NO20075136L/no
Priority to HK08105936.8A priority patent/HK1111625A1/xx
Priority to US12/891,568 priority patent/US8758810B2/en
Priority to US14/274,377 priority patent/US20140363491A1/en
Priority to CY20151100123T priority patent/CY1116075T1/el
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2005067469A 2005-03-10 2005-03-10 新規なリポソーム製剤 Pending JP2006248978A (ja)

Priority Applications (25)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤
HUE06737793A HUE024290T2 (en) 2005-03-10 2006-03-08 New liposome compositions
MX2007010996A MX2007010996A (es) 2005-03-10 2006-03-08 Nuevas composiciones de liposomas.
EP06737793.7A EP1863448B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
ZA200708600A ZA200708600B (en) 2005-03-10 2006-03-08 Novel liposome compositions
JP2008500977A JP5438317B2 (ja) 2005-03-10 2006-03-08 新規リポソーム組成物
RU2007137492/15A RU2454229C2 (ru) 2005-03-10 2006-03-08 Новые композиции липосом
BRPI0608297-1A BRPI0608297A2 (pt) 2005-03-10 2006-03-08 composições de lipossomos
CN2006800159670A CN101170995B (zh) 2005-03-10 2006-03-08 新颖的脂质体组合物
PT67377937T PT1863448E (pt) 2005-03-10 2006-03-08 Novas composições de lipossomas
CA002600446A CA2600446A1 (en) 2005-03-10 2006-03-08 Novel liposome compositions
AU2006223329A AU2006223329B2 (en) 2005-03-10 2006-03-08 Novel liposome compositions
PL06737793T PL1863448T3 (pl) 2005-03-10 2006-03-08 Nowe kompozycje liposomowe
SI200631892T SI1863448T1 (sl) 2005-03-10 2006-03-08 Novi liposomski sestavki
ES06737793.7T ES2529453T3 (es) 2005-03-10 2006-03-08 Nuevas composiciones de liposomas
KR1020077023219A KR101352490B1 (ko) 2005-03-10 2006-03-08 신규 리포좀 조성물
NZ561569A NZ561569A (en) 2005-03-10 2006-03-08 Novel liposome compositions comprising SuccNomegaPE:NomegaPE:additional lipids and TF-NomegaPE:NomegaPE:additional lipids
PCT/US2006/008650 WO2006099169A2 (en) 2005-03-10 2006-03-08 Novel liposome compositions
DK06737793.7T DK1863448T3 (en) 2005-03-10 2006-03-08 NEW LIPOSOM COMPOSITIONS
US11/371,586 US7829113B2 (en) 2005-03-10 2006-03-08 Liposome compositions
NO20075136A NO20075136L (no) 2005-03-10 2007-10-09 Nye liposompreparater
HK08105936.8A HK1111625A1 (en) 2005-03-10 2008-05-28 Novel liposome compositions
US12/891,568 US8758810B2 (en) 2005-03-10 2010-09-27 Liposome compositions
US14/274,377 US20140363491A1 (en) 2005-03-10 2014-05-09 Novel liposome compositions
CY20151100123T CY1116075T1 (el) 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤

Publications (1)

Publication Number Publication Date
JP2006248978A true JP2006248978A (ja) 2006-09-21

Family

ID=36992280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005067469A Pending JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤
JP2008500977A Expired - Fee Related JP5438317B2 (ja) 2005-03-10 2006-03-08 新規リポソーム組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008500977A Expired - Fee Related JP5438317B2 (ja) 2005-03-10 2006-03-08 新規リポソーム組成物

Country Status (22)

Country Link
US (3) US7829113B2 (US07829113-20101109-C00005.png)
EP (1) EP1863448B1 (US07829113-20101109-C00005.png)
JP (2) JP2006248978A (US07829113-20101109-C00005.png)
KR (1) KR101352490B1 (US07829113-20101109-C00005.png)
CN (1) CN101170995B (US07829113-20101109-C00005.png)
AU (1) AU2006223329B2 (US07829113-20101109-C00005.png)
BR (1) BRPI0608297A2 (US07829113-20101109-C00005.png)
CA (1) CA2600446A1 (US07829113-20101109-C00005.png)
CY (1) CY1116075T1 (US07829113-20101109-C00005.png)
DK (1) DK1863448T3 (US07829113-20101109-C00005.png)
ES (1) ES2529453T3 (US07829113-20101109-C00005.png)
HK (1) HK1111625A1 (US07829113-20101109-C00005.png)
HU (1) HUE024290T2 (US07829113-20101109-C00005.png)
MX (1) MX2007010996A (US07829113-20101109-C00005.png)
NO (1) NO20075136L (US07829113-20101109-C00005.png)
NZ (1) NZ561569A (US07829113-20101109-C00005.png)
PL (1) PL1863448T3 (US07829113-20101109-C00005.png)
PT (1) PT1863448E (US07829113-20101109-C00005.png)
RU (1) RU2454229C2 (US07829113-20101109-C00005.png)
SI (1) SI1863448T1 (US07829113-20101109-C00005.png)
WO (1) WO2006099169A2 (US07829113-20101109-C00005.png)
ZA (1) ZA200708600B (US07829113-20101109-C00005.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009096487A1 (ja) 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
WO2014025042A1 (ja) 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
JP2016512550A (ja) * 2013-03-13 2016-04-28 マリンクロッド エルエルシー がん治療のためのリポソームオキサリプラチン組成物
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173073A1 (en) 2004-05-03 2017-05-31 Merrimack Pharmaceuticals, Inc. Liposomes for drug delivery
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
ES2550759T3 (es) * 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
DK2194987T3 (en) 2007-09-10 2016-08-15 Boston Biomedical Inc Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors
EP2451950B9 (en) * 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
EP2558108A1 (en) * 2010-04-12 2013-02-20 Ramot at Tel-Aviv University Ltd Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
CA3118108C (en) 2010-11-12 2024-02-20 Oncour Pharma, Inc. Modified immune-modulating particles comprising poly(lactic acid)
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP2863942B1 (en) * 2012-06-21 2019-04-10 Northwestern University Peptide conjugated particles
AU2013360302C1 (en) 2012-12-12 2019-01-24 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US9913883B2 (en) 2013-03-13 2018-03-13 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
MX2015012199A (es) * 2013-03-13 2015-11-30 Mallinckrodt Llc Composiciones de cisplatino liposomal para la terapia contra el cancer.
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
HUE047329T2 (hu) 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
KR102523466B1 (ko) 2013-11-07 2023-04-20 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US20170007700A1 (en) * 2014-02-21 2017-01-12 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
EP3212165B1 (en) 2014-10-30 2024-02-28 President and Fellows of Harvard College Delivery of negatively charged proteins using cationic lipids
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
RU2695357C1 (ru) 2015-06-24 2019-07-23 Ниппон Каяку Кабусики Каися Новый комплекс платины (iv)
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
EP3351580B1 (en) 2015-09-14 2021-02-24 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex
CN108366965B (zh) 2015-10-16 2021-10-01 易普森生物制药有限公司 稳定喜树碱药物组合物
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
CA3009130A1 (en) 2015-12-22 2017-06-29 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of sulfoxide derivative-coordinated platinum(ii) complex
CN106995465B (zh) 2016-01-25 2019-11-01 沈阳药科大学 一种化合物及其应用以及一种铂类配合物及其脂质体
JP6606600B2 (ja) * 2016-04-15 2019-11-13 富士フイルム株式会社 マイクロニードルアレイ
CA3032810A1 (en) * 2016-08-02 2018-02-08 Curirx Inc. Methods for the preparation of liposomes
IL264565B1 (en) 2016-08-03 2024-03-01 Harvard College Adenosine nuclear base editors and their uses
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
BR112019002495A2 (pt) 2016-08-12 2019-05-14 L.E.A.F. Holdings Group Llc antifolatos poliglutamatados e seus usos
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP2019530464A (ja) 2016-10-14 2019-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
MX2019004783A (es) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3634385A4 (en) * 2017-05-12 2021-03-03 Curinanorx, LLC LIPOSOME PREPARATION PROCESSES INCLUDING MEDICINAL PRODUCTS
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
CA3113472A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
KR20210093232A (ko) 2018-10-09 2021-07-27 더 유니버시티 오브 브리티시 콜롬비아 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
WO2020191239A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (US07829113-20101109-C00005.png) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
EP0211042A1 (en) * 1985-01-18 1987-02-25 Cooper-Lipotech, Inc. Liposome composition and method
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
ATE233100T1 (de) * 1989-08-02 2003-03-15 Mitra Medical Technology Ab System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2093665A1 (en) * 1990-10-09 1992-04-10 Sean M. Sullivan Phospholipid analogue vesicle
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) * 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JPH06287021A (ja) * 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US20030100489A1 (en) * 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
CA2150939C (en) * 1993-10-06 2001-05-01 David Collins Stable protein: phospholipid compositions and methods
WO1995016774A1 (en) * 1993-12-17 1995-06-22 Spinal Cord Society Method for inducing dna synthesis in neurons
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
JP3590983B2 (ja) * 1994-03-04 2004-11-17 日本油脂株式会社 リン脂質誘導体
CA2185810A1 (en) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
PT773921E (pt) 1994-07-29 2000-05-31 Abbott Lab Processo para a preparacao de um 2,5-diamino-2-hidroxi-hexano substituido
UA42779C2 (uk) 1994-08-08 2001-11-15 Дебіофарм С.А. Фармацевтично стійкий препарат оксалату платини для парентерального застосування
ATE198419T1 (de) * 1994-10-14 2001-01-15 Liposome Co Inc Etherlipid-liposomen und deren therapeutische verwendung
DE69531722T2 (de) 1994-11-11 2004-07-01 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (US07829113-20101109-C00005.png) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
WO1997028817A1 (en) * 1996-02-09 1997-08-14 Cheng Pi Wan Receptor ligand-facilitated delivery of biologically active molecules
US6153646A (en) 1996-03-11 2000-11-28 Yoshinori Kidani Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
US6197333B1 (en) * 1996-03-28 2001-03-06 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
US6228391B1 (en) * 1996-05-02 2001-05-08 Terumo Kabushiki Kaisha Amidine derivatives and drug carriers comprising the same
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
AU725257B2 (en) 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
DK0964690T3 (da) * 1996-10-15 2003-10-20 Liposome Co Inc Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration
US6153596A (en) 1996-12-18 2000-11-28 Emory University Polycationic oligomers
CA2281807C (en) 1997-03-07 2007-10-16 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
JPH10253632A (ja) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
EP1007564A4 (en) * 1997-07-15 2002-09-18 Univ California ISOLATED DNA ENCODING A HUMAN POTASSIUM-ACTIVATED POTASSIUM CHANNEL
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
EP1019094B1 (en) * 1997-10-02 2003-11-19 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6573101B1 (en) * 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) * 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
BRPI9914508B8 (pt) * 1998-10-14 2021-05-25 Debiopharm Sa bolsa flexível impermeável para uso médico contendo uma preparação farmacêutica de oxaliplatina sob a forma líquida
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2000069915A2 (en) 1999-05-17 2000-11-23 Avi Biopharma, Inc. COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) * 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
EP1204241A1 (en) * 1999-08-09 2002-05-08 Fujitsu Limited Package control device and method
CA2382389C (fr) 1999-08-30 2010-06-29 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
AU3366901A (en) 1999-12-30 2001-07-16 Novartis Ag Novel colloid synthetic vectors for gene therapy
BR0016864A (pt) 1999-12-30 2002-09-24 Judith K Gwathmey Sistema de fornecimento de quelante de ferro, e, métodos de preparação de um sistema de fornecimento de quelante de ferro e de tratamento de sobrecarga de ferro em um mamìfero em necessidade de tratamento
US7034006B2 (en) * 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
ATE374785T1 (de) * 2000-03-02 2007-10-15 Mitsubishi Pharma Corp Gpib-gebundenes konstrukt und verwendungen davon
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
ATE382333T1 (de) 2000-04-12 2008-01-15 Liplasome Pharma As Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
CZ20023913A3 (cs) * 2000-05-03 2003-09-17 Munich Biotech Ag Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
CA2421872A1 (en) * 2000-09-11 2002-03-14 Institut Pasteur Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
US20040126431A1 (en) * 2000-10-03 2004-07-01 Frederic Lagarce Method for preparing microspheres containing a water-soluble substance
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
WO2002041870A2 (en) 2000-11-22 2002-05-30 Vectron Therapeutics Ag Production and use of a targeted diagnostic system
CN1559007A (zh) * 2000-12-12 2004-12-29 澳大利亚海洋科学研究院 致瘫痪水生有壳类动物毒素的分析
WO2002047725A2 (fr) * 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
EP1368022B1 (fr) 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
CA2445947A1 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) * 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
AU2002330139A1 (en) * 2001-10-03 2003-04-14 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
US7101985B2 (en) 2001-11-20 2006-09-05 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
ATE477276T1 (de) * 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2004065621A1 (en) * 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
CA2488753A1 (en) * 2002-06-07 2003-12-18 Immunomedics, Inc. Neutrophil imaging methods in cyctic fibrosis
CA2489467C (en) * 2002-06-14 2015-02-24 Immunomedics, Inc. Humanized monoclonal antibody hpam4
WO2003106497A1 (en) * 2002-06-14 2003-12-24 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
DK1519714T3 (da) * 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
AU2003248982B2 (en) 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
WO2004045519A2 (en) 2002-11-14 2004-06-03 Kirk Sperber Induction of apoptosis by hiv-1 infected monocytic cells
WO2004045583A1 (ja) 2002-11-15 2004-06-03 Nipro Corporation リポソーム
MXPA05008687A (es) 2003-02-17 2005-10-05 Mebiopharm Co Ltd Remedio para cancer.
AU2004232928A1 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US7172751B2 (en) * 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
WO2005012493A2 (en) * 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
EP1579850A3 (en) 2004-03-15 2009-12-16 Nipro Corporation A pharmaceutical composition containing liposomes for treating a cancer
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP5345792B2 (ja) 2008-02-19 2013-11-20 テイ・エス テック株式会社 車両用格納シート
JP5331648B2 (ja) 2009-10-22 2013-10-30 株式会社日立製作所 微粉炭ボイラの改造方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009096487A1 (ja) 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
JP5419716B2 (ja) * 2008-01-30 2014-02-19 国立大学法人徳島大学 オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US8940327B2 (en) 2008-01-30 2015-01-27 The University Of Tokushima Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
JPWO2014025042A1 (ja) * 2012-08-10 2016-07-25 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
WO2014025042A1 (ja) 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
US10383822B2 (en) 2012-08-10 2019-08-20 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
US10993913B2 (en) 2012-08-10 2021-05-04 Taiho Pharmaceutical Co., Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
JP2016512550A (ja) * 2013-03-13 2016-04-28 マリンクロッド エルエルシー がん治療のためのリポソームオキサリプラチン組成物
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
US11655469B2 (en) 2016-03-07 2023-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MicroRNAs and methods of their use
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US11795459B2 (en) 2020-04-02 2023-10-24 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Also Published As

Publication number Publication date
EP1863448A2 (en) 2007-12-12
US7829113B2 (en) 2010-11-09
HUE024290T2 (en) 2016-01-28
PT1863448E (pt) 2015-02-10
KR20080002819A (ko) 2008-01-04
US8758810B2 (en) 2014-06-24
NO20075136L (no) 2007-12-07
CA2600446A1 (en) 2006-09-21
US20110081404A1 (en) 2011-04-07
RU2454229C2 (ru) 2012-06-27
JP2008538105A (ja) 2008-10-09
WO2006099169A2 (en) 2006-09-21
AU2006223329B2 (en) 2011-11-17
DK1863448T3 (en) 2015-02-16
US20060222696A1 (en) 2006-10-05
US20140363491A1 (en) 2014-12-11
ZA200708600B (en) 2009-01-28
JP5438317B2 (ja) 2014-03-12
CN101170995A (zh) 2008-04-30
ES2529453T3 (es) 2015-02-20
HK1111625A1 (en) 2008-08-15
WO2006099169A3 (en) 2007-02-22
RU2007137492A (ru) 2009-04-20
NZ561569A (en) 2011-03-31
CY1116075T1 (el) 2017-02-08
PL1863448T3 (pl) 2015-05-29
KR101352490B1 (ko) 2014-02-04
MX2007010996A (es) 2007-11-07
BRPI0608297A2 (pt) 2009-12-08
AU2006223329A1 (en) 2006-09-21
SI1863448T1 (sl) 2015-03-31
EP1863448B1 (en) 2014-11-26
CN101170995B (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
JP2006248978A (ja) 新規なリポソーム製剤
JP3415131B1 (ja) リポソーム製剤
JP5871930B2 (ja) ナノ粒子ベースの腫瘍標的化薬剤送達
Omokawa et al. In vitro and in vivo anti-tumor effects of novel Span 80 vesicles containing immobilized Eucheuma serra agglutinin
BRPI0610026A2 (pt) composição de imunolipossoma para direcionamento a um receptor celular her2
WO2008030818A2 (en) Novel liposome compositions
US20210213051A1 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
JP2018530623A (ja) ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
US20150017098A1 (en) Carrier that targets fucosylated molecule-producing cells
CN113307824B (zh) 一种双亲性材料及其在制备脂质体中的应用
JP2020521004A (ja) ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
KR102540728B1 (ko) 면역세포-나노리포좀 복합체 및 이의 제조 방법
Wang et al. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery
EP2668961A1 (en) Combined pharmaceutical preparation
CN112843245A (zh) 一种具有肿瘤特异性的ppb增敏剂及其合成方法和用途
WO2011005714A2 (en) Bendamustine liposomal compositions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080226

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20090113